RHÖN-KLINIKUM AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
May 28, 2020 at 10:05 am
Share
DGAP Voting Rights Announcement: RHÖN-KLINIKUM Aktiengesellschaft
RHÖN-KLINIKUM AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
28.05.2020 / 16:00
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Notification of Major Holdings
1. Details of issuer
Name:
RHÖN-KLINIKUM Aktiengesellschaft
Street:
Salzburger Leite 1
Postal code:
97616
City:
Bad Neustadt a.d.Saale Germany
Legal Entity Identifier (LEI):
529900MVGMIVUDQY9E20
2. Reason for notification
X
Acquisition/disposal of shares with voting rights
X
Acquisition/disposal of instruments
Change of breakdown of voting rights
Other reason:
3. Details of person subject to the notification obligation
Natural person (first name, surname): Dr. Bernard große Broermann Date of birth: 20 Nov 1943
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
AMR Holding GmbH
5. Date on which threshold was crossed or reached:
26 May 2020
6. Total positions
% of voting rights attached to shares (total of 7.a.)
% of voting rights through instruments (total of 7.b.1 + 7.b.2)
Total of both in % (7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New
42.95 %
7.66 %
50.07 %
66962470
Previous notification
28.99 %
49.77 %
50.07 %
/
7. Details on total positions a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN
Absolute
In %
Direct (Sec. 33 WpHG)
Indirect (Sec. 34 WpHG)
Direct (Sec. 33 WpHG)
Indirect (Sec. 34 WpHG)
DE0007042301
360
28,763,252
0.0005 %
42.95 %
Total
28,763,612
42.95 %
b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Voting rights absolute
Voting rights in %
Right to transfer shares under share purchase agreement of 28 February 2020
4,405,517
6.58 %
Right to transfer shares under share purchase agreement of 1 March 2020
361,430
0.54 %
Total
4,766,947
7.12 %
b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Cash or physical settlement
Voting rights absolute
Voting rights in %
contribution obligation subject to a condition precedent under joint venture agreement
4,405,517
6.58 %
contribution obligation subject to a condition precedent under joint venture agreement
722,860
1.08 %
Total
5,128,377
7.66 %
8. Information in relation to the person subject to the notification obligation
Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X
Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:
Name
% of voting rights (if at least 3% or more)
% of voting rights through instruments (if at least 5% or more)
Total of both (if at least 5% or more)
Dr. Benard große Broermann
%
%
%
Asklepios KlinikenManagement GmbH
%
%
%
Asklepios Kliniken GmbH & Co. KGaA
%
%
%
AMR Holding GmbH
42.11 %
7.66 %
49.77 %
Dr. Bernard große Broermann
%
%
%
Broermann Holding GmbH
%
%
%
Asklepios Kliniken GmbH & Co. KGaA
%
%
%
AMR Holding GmbH
42.11 %
7.66 %
49.77 %
9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)
Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights
Proportion of instruments
Total of both
%
%
%
10. Other explanatory remarks:
The Asklepios Kliniken GmbH & Co. KGaA ("Asklepios") acquired a shareholding in RHÖN-KLINIKUM AG ("RHÖN") of 5.81% (from a total of 12.39%) on 26.5.2020 based on the share purchase agreement with E. Münch and I. Münch dated 28.2.2020 and contributed this to AMR Holding GmbH ("AMR") on the same day together with the RHÖN shares already held directly by Asklepios (34.49% in total) in accordance with the joint venture agreement dated 28.2.2020 ("JVV"). On 26.5.2020, HCM SE contributed a 7.61% stake to AMR in accordance with the JVV. On 26.5.2020, Asklepios acquired a shareholding of 0.54% (of a total of 1.08%) based on the share purchase agreement with the Münch Foundation dated 1.3.2020. Asklepios is obliged under the JVV to contribute this shareholding to AMR. To avoid double counting, the voting rights and instruments held by Asklepios were offset according to section 38 (1) sentence 1 of the WpHG and the instruments held by AMR according to section 38 (1) sentence 1 no. 2 of the WpHG.
Date
27 May 2020
28.05.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Rhoen Klinikum AG is a Germany-based provider of health care services. The Company operates acute hospitals, medical care centers, and rehabilitation hospitals across Germany: six clinics on Campus Bad Neustadt, including the Cardiovascular Clinic, the Frankenklinik for the Rehabilitation of Cardiovascular Patients, the Clinic for Hand Surgery, the Neurological Clinic, the Psychosomatic clinic and the Saaletalklinik with two additional addiction therapy facilities; Klinikum Frankfurt (Oder) comprises clinics, psychiatric outpatient institutions, and day clinics; University Hospital Giessen and Marburg (UKGM) offers medical services, modern diagnostics and comprehensive therapy in various areas, including ophthalmology, trauma surgery and dentistry, and Zentralklinik Bad Berka provides health care services to patients with thoracic, pulmonary and vascular diseases, tumors, neurological conditions, and diseases of the spinal column, joints and heart, among others.
RHÖN-KLINIKUM AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution